Press Releases

Date Title
Sep 03, 2024 Chimerix to Present at H.C. Wainwright 26th Annual Global Investment Conference
DURHAM, N.C. , Sept. 03, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Andriole , Chief Executive Officer, will
Aug 30, 2024 Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C. , Aug. 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on August 20, 2024 , the Compensation Committee of Chimerix’s Board of Directors granted an inducement award to a new employee of non-statutory stock options to purchase up to a total of 150,000 shares of
Aug 13, 2024 Chimerix Reports Second Quarter 2024 Financial Results and Provides Operational Update
      – Phase 3 ACTION Study On-Track; First Interim Overall Survival Data Expected Third Quarter 2025 – – ONC206 Phase 1 PK and Safety Data Demonstrate Dose Proportional Exposure with No Dose Limiting Toxicity to Date – – Dordaviprone Filed for Provisional Determination with Therapeutic Goods
Aug 06, 2024 Chimerix to Report Second Quarter 2024 Financial Results and Provide an Operational Update on August 13, 2024
DURHAM, N.C. , Aug. 06, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on
Jul 05, 2024 Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C. , July 05, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on July 1, 2024 , the Compensation Committee of Chimerix’s Board of Directors granted inducement awards to two new employees of non-statutory stock options to purchase up to a total of 120,000 shares of
May 30, 2024 Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference
DURHAM, N.C. , May 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Andriole , Chief Executive Officer, will
May 01, 2024 Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update
– Dordaviprone (ONC201) ACTION Study Progressing; Reiterates Expectations for Interim Overall Survival (OS) Data in 2025 and Final OS Data in 2026 – – No Dose Limiting Toxicity in ONC206 Phase 1 Studies to Date, Preliminary Phase 1 Safety and Pharmacokinetic (PK) Data Expected This Summer – –
Apr 24, 2024 Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024
DURHAM, N.C. , April 24, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast
Apr 16, 2024 Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C. , April 16, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX) today announced that on April 10, 2024 , the Compensation Committee of Chimerix’s Board of Directors granted inducement awards to four new employees of non-statutory stock options to purchase up to a total of 223,000 shares of
Mar 21, 2024 Chimerix Appoints Marc D. Kozin to Board of Directors
Veteran Industry Executive Brings More Than 35 Years of Corporate Strategy Experience DURHAM, N.C. , March 21, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly
Displaying 1 - 10 of 13
  • Print
  • Email Alerts
  • RSS Feeds
  • Search
  • Share
scroll back to top of page